Another study showed that a therapy targeting FAP+ cells that express CXCL12 synergized with anti-PD-L1 immunotherapy in PDAC [121], and inhibition of its receptor, CXCR4, in sorafenib-treated HCC facilitates anti-PDL-1 immunotherapy [253]. Here, CD274 is linked to hepatocellular carcinoma.